FANDOM


Reboxetine
Reboxetine
Synonyms FCE-20124
Brand names Edronax, Prolift
IUPAC name

IUPAC name
(2S)-2-[(S)-2-ethoxyphenoxy(phenyl)methyl]morpholine
ChemSpider

59268

DrugBank

DB01149

PubChem

65856

PDB fields

N/A

Formula

C19H23N5O3

InChI
InChI
1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1
InChIKey
InChIKey
CBQGYUDMJHNJBX-OALUTQOASA-N
SMILES
SMILES
[H][C@]1(CNCCO1)[C@@H](OC1=CC=CC=C1OCC)C1=CC=CC=C1
(Jmol 3D structure)
Mol. mass

313.3908 g/mol

Reboxetine is a selective noradrenaline reuptake inhibitor (not totally selective, a slight serotonin reuptake inhibition is seen at clinical doses), that according to at least one systematic review is ineffective and potentially dangerous,[1] whereas according to one it is effective and safe.[2]:378-380 It has never been approved by the FDA, although it is used in the remainder of the developed world (including Australia, the U.K., Germany, New Zealand, etc.), aside from Canada and Singapore.[3] It is taken twice a day and has been used off-label for the treatment of ADHD, obesity, panic disorder, narcolepsy and potentially, cocaine dependence.[3][4] Its principal side effects include urinary problems (like difficulty passing urine) and side effects you would expect for a sympathomimetic, such as insomnia, anti-parasympathomimetic effects like dry mouth, constipation, blurred vision, etc.; increased sweating, high heart rate, hypertension, etc.[3]

External linksEdit

Reference listEdit

  1. Eyding, D; Lelgemann, M; Grouven, U; Härter, M; Kromp, M; Kaiser, T; Kerekes, MF; Gerken, M; Wieseler, B (October 2010). "Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.". BMJ 341: c4737. PMC 2954275. PMID 20940209. doi:10.1136/bmj.c4737. 
  2. National Collaborating Centre for Mental Health (2010). Depression: the NICE guideline on the treatment and management of depression in adults (PDF) (Updated ed. ed.). London, UK: Royal College of Psychiatrists. ISBN 978-1-904671-85-5. PMID 22132433. 
  3. 3.0 3.1 3.2 Brayfield, A, ed. (8 November 2011). "Reboxetine Mesilate". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 10 August 2014. 
  4. Sepede, G; Corbo, M; Fiori, F; Martinotti, G (July 2012). "Reboxetine in clinical practice: a review.". La Clinica Terapeutica 163 (4): e255–62. PMID 23007832. 

Ad blocker interference detected!


Wikia is a free-to-use site that makes money from advertising. We have a modified experience for viewers using ad blockers

Wikia is not accessible if you’ve made further modifications. Remove the custom ad blocker rule(s) and the page will load as expected.